Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

[A clinical study on the efficacy of HBeAg-positive chronic hepatitis B patients treated with adefovir dipivoxil for 4 years].

Liang JY, Yang XA, Zhang K, Chen LB, Shu X, Xu QH.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2011 Oct;25(5):384-6. Chinese.

PMID:
22338232
2.

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F.

N Engl J Med. 2008 Dec 4;359(23):2442-55. doi: 10.1056/NEJMoa0802878.

3.

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL; Adefovir Dipivoxil 438 Study Group.

Gastroenterology. 2006 Dec;131(6):1743-51. Epub 2006 Sep 20.

PMID:
17087951
4.

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL; Adefovir Dipivoxil 437 Study Group.

N Engl J Med. 2003 Feb 27;348(9):808-16.

5.

[Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].

Ling N, Zhou Z, Zhang DZ, Ren H.

Zhonghua Gan Zang Bing Za Zhi. 2007 May;15(5):346-9. Chinese.

PMID:
17524266
6.

[A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].

Yang Q, Gong ZJ, Hu DF.

Zhonghua Gan Zang Bing Za Zhi. 2009 Jul;17(7):515-9. Chinese.

PMID:
19912686
8.

Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study.

Lu H, Geng da Y, Shen F, Zhang JY, Lu B, Ma LX.

Virol J. 2011 Sep 21;8:444. doi: 10.1186/1743-422X-8-444.

9.

[Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].

Zhou HJ, Li SG, Wen FY, Yang XY, Wu JL, Tan B, Fu J.

Zhonghua Gan Zang Bing Za Zhi. 2009 Aug;17(8):564-8. Chinese.

PMID:
19719911
10.

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Arterburn S, Xiong S, Currie G, Brosgart CL; Adefovir Dipivoxil 438 Study Group.

N Engl J Med. 2005 Jun 30;352(26):2673-81.

11.

[Relationship between HBeAg seroconversion with genotypes and HBV specific CTL in patients with chronic hepatitis B treated with Adefovir dipivoxil].

Zhou YL, Wang XC, Wu YT, Tan YF, Zhao YP, Tang JM, Pan JQ, Yang ZX, Gu XB.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2011 Jun;25(3):220-3. Chinese.

PMID:
21977598
12.

Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B.

He Z, Wang J, Liu K, Huang H, Du Y, Lin Z, Cai M, Feng X.

Clin Res Hepatol Gastroenterol. 2012 Dec;36(6):592-7. doi: 10.1016/j.clinre.2012.05.012. Epub 2012 Oct 12.

PMID:
23069315
14.

[The analyse of effectiveness in HBeAg-positive chronic viral hepatitis B treated by adefovir dipivoxil combined with bicyclol].

Xiang DR, Sheng JF.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2009 Aug;23(4):299-301. Chinese.

PMID:
20108779
15.

Treatment of patients with chronic hepatitis B with adefovir dipivoxil.

Tong MJ, Tu SS.

Semin Liver Dis. 2004;24 Suppl 1:37-44. Review.

PMID:
15192800
16.

[The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].

Moon JH, Cho M, Yoon KT, Bae JH, Heo J, Kim GH, Kang DH, Song GA.

Korean J Hepatol. 2008 Dec;14(4):503-12. doi: 10.3350/kjhep.2008.14.4.503. Korean.

17.

HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy.

Tseng KC, Cheng PN, Wu IC, Chang CK, Chou AL, Liu WC, Chang TT.

Hepatogastroenterology. 2009 May-Jun;56(91-92):813-8.

PMID:
19621708
18.

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

Peters MG, Hann Hw Hw, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray Df Df, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart CL.

Gastroenterology. 2004 Jan;126(1):91-101.

PMID:
14699491
19.

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F.

Hepatology. 2008 Sep;48(3):750-8. doi: 10.1002/hep.22414.

PMID:
18752330
20.

Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.

Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, Mecenate F, Paffetti A, Barlattani A, Struglia C, Villani R, Nauri L, Nosotti L, Armignacco O, Ferri F, Camporiondo MP, Soccorsi F; Club Epatologi Ospedalieri (CLEO) Group.

Clin Ther. 2008 Feb;30(2):317-23. doi: 10.1016/j.clinthera.2008.02.012.

PMID:
18343270

Supplemental Content

Support Center